Evidence map›Paper›PMID 24797675›Full record

ArticlePloS one2014

Direct evidence for pitavastatin induced chromatin structure change in the KLF4 gene in endothelial cells.

Takashi Maejima, Tsuyoshi Inoue, Yasuharu Kanki, Takahide Kohro, Guoliang Li, Yoshihiro Ohta, Hiroshi Kimura, Mika Kobayashi, Akashi Taguchi, Shuichi Tsutsumi and 31 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 49 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Transcription factors regulating vasculogenesis and angiogenesis.Developmental dynamics : an official publication of the American Association of Anatomists · 2024
    Review
  12. Article
  13. Article
  14. TGFβ signaling pathways in human health and disease.Frontiers in molecular biosciences · 2023
    Review
  15. Review
  16. Article
  17. The MEK5/ERK5 Pathway in Health and Disease.International journal of molecular sciences · 2021
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

41 authors at 8 institutions in 3 countries.

Takashi MaejimaResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro-ku, Tokyo, Japan; Tokyo New Drug Research Laboratories, Kowa Company Ltd., Higashimurayama, Tokyo, Japan.
Tsuyoshi InoueResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro-ku, Tokyo, Japan; Division of Nephrology and Endocrinology, The University of Tokyo School of Medicine, Bunkyo-ku, Tokyo, Japan.
Yasuharu KankiResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro-ku, Tokyo, Japan.
Takahide KohroResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro-ku, Tokyo, Japan; Department of Translational Research for Healthcare and Clinical Science, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Guoliang LiJackson Laboratory for Genomic Medicine, Farmington, Connecticut, United States of America.
Yoshihiro OhtaResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro-ku, Tokyo, Japan.
Hiroshi KimuraGraduate School of Frontier Biosciences, Osaka University, Suita, Osaka, Japan.
Mika KobayashiResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro-ku, Tokyo, Japan.
Akashi TaguchiResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro-ku, Tokyo, Japan.
Shuichi TsutsumiResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro-ku, Tokyo, Japan.
Hiroko IwanariResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro-ku, Tokyo, Japan.
Shogo YamamotoResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro-ku, Tokyo, Japan.
Hirofumi ArugaThermo Fisher Scientific, South San Francisco, California, United States of America.
Shoulian DongThermo Fisher Scientific, South San Francisco, California, United States of America.
Junko F StevensThermo Fisher Scientific, South San Francisco, California, United States of America.
Huay Mei PohJackson Laboratory for Genomic Medicine, Farmington, Connecticut, United States of America.
Kazuki YamamotoResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro-ku, Tokyo, Japan.
Takeshi KawamuraResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro-ku, Tokyo, Japan.
Imari MimuraResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro-ku, Tokyo, Japan; Division of Nephrology and Endocrinology, The University of Tokyo School of Medicine, Bunkyo-ku, Tokyo, Japan.
Jun-ichi SuehiroResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro-ku, Tokyo, Japan.
Akira SugiyamaResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro-ku, Tokyo, Japan.
Kiyomi KanekiResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro-ku, Tokyo, Japan.
Haruki ShibataTokyo New Drug Research Laboratories, Kowa Company Ltd., Higashimurayama, Tokyo, Japan.
Yasunobu YoshinakaTokyo New Drug Research Laboratories, Kowa Company Ltd., Higashimurayama, Tokyo, Japan.
Takeshi DoiTokyo New Drug Research Laboratories, Kowa Company Ltd., Higashimurayama, Tokyo, Japan.
Akimune AsanumaTokyo New Drug Research Laboratories, Kowa Company Ltd., Higashimurayama, Tokyo, Japan.
Sohei TanabeTokyo New Drug Research Laboratories, Kowa Company Ltd., Higashimurayama, Tokyo, Japan.
Toshiya TanakaResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro-ku, Tokyo, Japan.
Takashi MinamiResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro-ku, Tokyo, Japan.
Takao HamakuboResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro-ku, Tokyo, Japan.
Juro SakaiResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro-ku, Tokyo, Japan.
Naohito NozakiMab Institute Inc., North Advancement Center for Science & Technology, Sapporo, Hokkaido, Japan.
Hiroyuki AburataniResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro-ku, Tokyo, Japan.
Masaomi NangakuDivision of Nephrology and Endocrinology, The University of Tokyo School of Medicine, Bunkyo-ku, Tokyo, Japan.
Xiaoan RuanGenome Institute of Singapore, Singapore, Singapore.
Hideyuki TanabeDepartment of Evolutionary Studies of Biosystems, School of Advanced Sciences, The Graduate University for Advanced Studies (Sokendai), Hayama, Kanagawa, Japan.
Yijun RuanJackson Laboratory for Genomic Medicine, Farmington, Connecticut, United States of America.
Sigeo IharaResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro-ku, Tokyo, Japan.
Akira EndoBiopharm Research Laboratories, Inc., Koganei, Tokyo, Japan.
Tatsuhiko KodamaResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro-ku, Tokyo, Japan.
Youichiro WadaResearch Center for Advanced Science and Technology, The University of Tokyo, Meguro-ku, Tokyo, Japan; Radioisotope Center, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
The University of Tokyo · JPKowa (Japan) · JPJackson Laboratory · USThermo Fisher Scientific (United States) · USGenome Institute of Singapore · SGNorth Advancement Center for Science and Technology · JPOsaka University · JPThe Graduate University for Advanced Studies, SOKENDAI · JP

Funding

Shared Resource ManagementP30CA034196 · NCI · JACKSON LABORATORY · PI William Carl Skarnes · 1985 to 2026
$61.9M
NCI NIH HHS P30 CA034196
6 · The paper itself

Abstract

Statins exert atheroprotective effects through the induction of specific transcriptional factors in multiple organs. In endothelial cells, statin-dependent atheroprotective gene up-regulation is mediated by Kruppel-like factor (KLF) family transcription factors. To dissect the mechanism of gene regulation, we sought to determine molecular targets by performing microarray analyses of human umbilical vein endothelial cells (HUVECs) treated with pitavastatin, and KLF4 was determined to be the most highly induced gene. In addition, it was revealed that the atheroprotective genes induced with pitavastatin, such as nitric oxide synthase 3 (NOS3) and thrombomodulin (THBD), were suppressed by KLF4 knockdown. Myocyte enhancer factor-2 (MEF2) family activation is reported to be involved in pitavastatin-dependent KLF4 induction. We focused on MEF2C among the MEF2 family members and identified a novel functional MEF2C binding site 148 kb upstream of the KLF4 gene by chromatin immunoprecipitation along with deep sequencing (ChIP-seq) followed by luciferase assay. By applying whole genome and quantitative chromatin conformation analysis {chromatin interaction analysis with paired end tag sequencing (ChIA-PET), and real time chromosome conformation capture (3C) assay}, we observed that the MEF2C-bound enhancer and transcription start site (TSS) of KLF4 came into closer spatial proximity by pitavastatin treatment. 3D-Fluorescence in situ hybridization (FISH) imaging supported the conformational change in individual cells. Taken together, dynamic chromatin conformation change was shown to mediate pitavastatin-responsive gene induction in endothelial cells.

Indexed as

ChromatinChromatin Assembly and DisassemblyGene Expression RegulationGene Knockdown TechniquesHumansHuman Umbilical Vein Endothelial CellsHydroxymethylglutaryl-CoA Reductase InhibitorsKruppel-Like Factor 4Kruppel-Like Transcription FactorsMEF2 Transcription FactorsNitric Oxide Synthase Type IIIQuinolinesResponse ElementsThrombomodulinChromatinHydroxymethylglutaryl-CoA Reductase InhibitorsKLF4 protein, humanKruppel-Like Factor 4Kruppel-Like Transcription FactorsMEF2C protein, humanMEF2 Transcription FactorsNitric Oxide Synthase Type IIINOS3 protein, humanpitavastatinQuinolinesThrombomodulin

Identifiers

PMID24797675
PMCPMC4010393
OpenAlexW2035940398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.